This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) highlights recent advances in biological therapies such as RNA therapies, biosimilars, gene therapies and cell therapies for the management of diseases such as cancer, neurodegenerative disorders and rare diseases. The research also provides technological insights across new developments in radiopharmaceutical medicines, molecular diagnostics and AI-powered imaging and management of inflammatory conditions.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Vascular Endothelial Growth Factor (VEGF) Inhibitor, Biosimilars, Ophthalmology, Kidney, Oligonucleotide Therapy, RNAi Therapy, AI-driven bioengineering, Gene Therapy, Pediatrics, Precision Oncology, Autoimmune Therapies, Cancer, Alpha-emitting Radiopharmaceuticals, NLRP3 Inflammasome, Chronic Inflammation, Glycan-based Diagnostics, Cancer Detection, Covalent Protein, Modular Scaffold, Multispecific Antibodies, Ganglioside Biomarker, Ovarian Cancer, CFTR Gene, Mutation, Pluripotent Neuronal Cells, Brain Cell Function, Neurodegenerative Disease, AI-powered Imaging, Stem Cell Differentiation, Immune Cell Engagers, Engineered B Cell Medicines, Allogeneic Therapies, Rare Disease, Cardiac Remodeling, Oligonucleotide Inhibitor, T Cell Receptor Engineering, Functional Screening, Antisense Oligonucleotide, Muscular Dystrophy-1